2026-01-08 :
NALIRIFOX protocol as a new standard of care for metastatic pancreatic cancer
Summary. The treatment of metastatic pancreatic cancer remains a major clinical challenge, with minimal therapeutic progress over many years. The introduction of NALIRIFOX represents an important step forward: the NAPOLI-3 study demonstrated its ability to improve first-line treatment outcomes. The article is devoted to the analysis of the evolution of systemic therapy for metastatic pancreatic cancer and the justification of the role of the NALIRIFOX protocol as a new standard of first-line therapy. Based on contemporary clinical trials, real-world evidence, and updated international guidelines, the article discusses the key advantages of the regimen, its efficacy, tolerability, and practical considerations for its use.
Leave a comment